uploads///Graph

Venclexta Witnessed Healthy Demand Trends in 1Q17

By

Dec. 4 2020, Updated 10:50 a.m. ET

Venclexta demand trends

AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11,2016. Venclexta witnessed robust demand in 1Q17 as a treatment option for patients who have relapsed/refractory chronic lymphocytic leukemia with 17p deletion. The drug has already captured 20% of the second line plus a share of this segment in US.

AbbVie has also successfully launched Venclexta in Germany and France. If the drug can realize rapid uptake in these international markets, it may have a positive impact on AbbVie stock, as well as on the Health Care Select Sector SPDR ETF (XLV). AbbVie makes up about 3.7% of XLV’s total portfolio holdings.

Article continues below advertisement

Research programs

AbbVie (ABBV) is expecting data from its Phase 3 trial, MURANO, evaluating the efficacy of the combination regimen of Venclexta and Roche Holdings’ (RHHBY) Rituxan. The regimen is being assessed as a treatment option for CLL patients irrespective of their 17p deletion status. The data is expected to be released in 2017. If the trial results are positive, AbbVie can seek regulatory approval for using Venclexta in broader CLL population.

AbbVie is also exploring the efficacy of Venclexta in CLL patients of different age groups, such as young and fit patients as well as older patients with other co-morbidities. These clinical trials, along with studies to evaluate the combination of Imbruvica and Venclexta, form part of the company’s larger strategy to move CLL patients to more chemo-free options.

AbbVie is also exploring Venclexta in other hematologic malignancies such as multiple myeloma and acute myeloid leukemia (or AML). Data from these Phase 3 trials is expected by 2019.

AbbVie is also anticipating data from Phase 2 trials evaluating Venclexta in indolent non-Hodgkin’s lymphoma (or iNHL) and diffuse large B-cell lymphoma (or DLBCL) in 2017.

With high chances of Venclexta proving even superior to Imbruvica in terms of efficacy and safety in CLL, AbbVie poses stiff competition to other oncology players such as Johnson & Johnson (JNJ), Pfizer (PFE), and Merck (MRK).

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.